Capivasertib (AZD5363)

Catalog No.S8019

Capivasertib (AZD5363) Chemical Structure

Molecular Weight(MW): 428.92

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 235 In stock
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 16 Publications

6 Customer Reviews

  • HEK293T cells stably expressing mTOR mutants (H1968Y, P2213S, and S2215Y) were constructed by TALEN. After nutrient starvation, wild-type (WT, for HEK293T cells not expressing mutants but wild-type mTOR after TALEN edition and selection) or mutated HEK293T cells (heterozygous, A) were treated with indicated inhibitors or vehicle. The activation of indicated molecules was examined by Western blotting.

    Clin Cancer Res, 2016, 22(4):1018-27. Capivasertib (AZD5363) purchased from Selleck.

    G-H. Analysis of cells treated with AZD5363 (500 nM) for 24 hrs. G.Western analysis of whole cell lysates. H. Cells labeled with Annexin V-FITC for 6h were imaged. Individual points are average for replicates assessed in duplicate. Midlines are the average ± S.D. Student’s T-test.

    Cancer Res, 2016, 76(16):4752-64.. Capivasertib (AZD5363) purchased from Selleck.

  • Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 uM AZD5363 (AZD) and 10 uM LY294002 (LY). Tubulin was used as a loading control.

    Cell Commun Signal 2014 12(1), 61. Capivasertib (AZD5363) purchased from Selleck.

    e HSP70 release induced by morphine was abrogated by AKT inhibitor. AZD5363 (AKT inhibitor, 2 μM) was given 15 min before morphine (200 μM, 12 h). Supernatants were collected and analyzed 12 h after morphine exposure (n = 3)

    J Neuroinflammation, 2017, 14(1):228. Capivasertib (AZD5363) purchased from Selleck.

  • (A) 239 cells stably expressing Flag-IL-17RA (293-IL-17RA cell line) were treated with 2 μM AZD5363 (a pan-Akt inhibitor) and/or 50 ng/ml insulin for the indicated time periods; Western blot analysis was performed for the indicated proteins; exogenous, IL-17RA transfected into 293 cells; endogenous, endogenous IL-17RA expressed in 293 cells.

    Oncotarget, 2016, 7(12):13651-66. Capivasertib (AZD5363) purchased from Selleck.

    LNCaP, LNCaP95, VCaP and 22Rv1 cells were transfected with control or pooled siRNA for AKT 1–3 isoforms for 36 hours. Cells were then further treated with 5 uM AZD5363 (B) for another 18 hours. Protein lysates were immunoblotted with AR (N-20), AR-V7, Pan-AKT, p-AKT(ser473) and β-Actin antibodies. Results were repeated in more than three independent experiments.

    PLoS One 2014 9(10), e108780. Capivasertib (AZD5363) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
Features Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. [1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. [2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLu[3MzODBibl2= NYq5WFhlPiCm NIH0dodqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= NFvzZVczPjN3MUOyNy=>
ZR75 NVzKfVhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNFAhdk1? NH;SOYQ3KGR? NYPD[XFNcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 M1nKd|I3OzVzM{Kz
T74D NESzNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC2NVAxKG6P NFXE[ZU3KGR? MmTEbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 NX;q[|h3OjZ|NUGzNlM>
1%MCF7 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXHb4Q1ODBibl2= M1P0fVYh\A>? MmPCbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 M2PBeVI3OzVzM{Kz
MCF7 LTED MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLHbJN{OjByIH7N MmnpOkBl NEjBSXpqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= NUnwXmEzOjZ|NUGzNlM>
ZR75 LTED NXrtWY5jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3hN4wyODBibl2= MWm2JIQ> MoDlbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 NHXnV24zPjN3MUOyNy=>
T74D LTED MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljWNVAxKG6P NHLmNW83KGR? NUnjOllIcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 NITWfVAzPjN3MUOyNy=>
TamR MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC0NFAhdk1? NXv0VFllPiCm M2HsfYlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= NIrHPZgzPjN3MUOyNy=>
HCC1954 MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\qNE0yNjN3IN88US=> NHvGfno2KGR? MlvR[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? NYDvPHlLOjZyOUW0O|U>
BT474c M2O3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[wMVEvOzVizszN MlHIOUBl NV\IdGI5\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= M3PtOlI3ODl3NEe1
KPL4 NGHPXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjFWnpVOC1zLkO1JO69VQ>? M{Ox[FUh\A>? MVnlcohidmOnczD0bIUh\3Kxd4ToJIlvcGmkaYTpc44hd2ZiQWrEPFk{OQ>? MUWyOlA6PTR5NR?=
SKBR3 NH:zSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzlNE0yNjN3IN88US=> NIrrN2I2KGR? NX7MSJBw\W6qYX7j[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJGFbTDh7M{G= NFPvflQzPjB7NUS3OS=>
MR49C NGPlWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGwMVUh|ryP M33kUFQ5KGh? NILDOpRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGPFO44zPTF3MUCxNi=>
MR49F NGjPd2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nQWVAuPSEQvF2= NUPMbGlLPDhiaB?= NYW2XmZmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NHLlTlYzPTF3MUCxNi=>
NCI-H522 NWqwPFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni1TWM2OD1zMT6zJEjDuTJwNzmg{txO NGW1[WIzPDl3N{[4Ni=>
PC-9 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\DSWlEPTB;OT6zJEjDuTFwMjmg{txO NIK3fJUzPDl3N{[4Ni=>
NCI-H522 NGXXV5lHfW6ldHnvckBCe3OjeR?= NWDLU2JmOS93L{GwJO69VQ>? M1zFW|QwOjRiaB?= NIroPVdqdmO{ZXHz[ZMhSUuWIIDoc5NxcG:{eXzheIlwdg>? NUTlN|ZzOjR7NUe2PFI>
PC-9 MnL3SpVv[3Srb36gRZN{[Xl? NHrZSGIyNzVxMUCg{txO NY[xelFWPC9{NDDo NUTxUXRRcW6lcnXhd4V{KEGNVDDwbI9{eGixconsZZRqd25? NEnMNpkzPDl3N{[4Ni=>
HGC27 NVnNXGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjhVHNKSzVyPUCuOFQ2KM7:TR?= Mn7QNlQxQDh|OEK=
IM95m NEXvdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nxNGlEPTB;MD61NUDPxE1? NI\rcnczPDB6OEO4Ni=>
AGS M3zYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n0NmlEPTB;MD61OVIh|ryP MnL3NlQxQDh|OEK=
NCI-N87 NHezeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4n6OWlEPTB;MT6wN|ch|ryP MkXuNlQxQDh|OEK=
23132/87 NVjGTo9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvtbFhtUUN3ME2xMlY4OSEQvF2= MnfrNlQxQDh|OEK=
MKN1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPJTWM2OD1{LkSyNUDPxE1? M33mcFI1ODh6M{iy
SNU-620 NHTOcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjLTWM2OD1|LkO4OEDPxE1? M2DpS|I1ODh6M{iy
SNU-638 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzJdHZKSzVyPUSuOVI{KM7:TR?= Mkj6NlQxQDh|OEK=
SNU-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXSW|NKSzVyPUWuNlU5KM7:TR?= MmfMNlQxQDh|OEK=
SNU-601 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\MSlhKSzVyPUWuPVM5KM7:TR?= NITIXXIzPDB6OEO4Ni=>
SNU-668 NXTRTGJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH0WndDUUN3ME22MlAxOyEQvF2= MorHNlQxQDh|OEK=
HS746T Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfCdWhHUUN3ME22MlA5PCEQvF2= MWqyOFA5QDN6Mh?=
KATO III NVTTW4V1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ixVGlEPTB;Nz6yOlch|ryP MkHuNlQxQDh|OEK=
SNU-484 NUfLVYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PCWWlEPTB;Nz6zPVIh|ryP MWOyOFA5QDN6Mh?=
SNU-16 NEXzNlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L2U2lEPTB;MUGuNFk4KM7:TR?= MmnMNlQxQDh|OEK=
OCUM-1 NH[zd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PXSGlEPTB;MUSuOVE2KM7:TR?= M1TD[|I1ODh6M{iy
NUGC-3 NH24UVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJzLki3N{DPxE1? M1OzWFI1ODh6M{iy
AZ521 M1rqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X0NmlEPTB;MkWuOFQ5KM7:TR?= MkHzNlQxQDh|OEK=
SNU-216 M2jSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXCNHJKSzVyPUOwJO69VQ>? MnnQNlQxQDh|OEK=
NUGC-4 M2Gy[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNyIN88US=> M{C2TFI1ODh6M{iy
SNU-5 NILJdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7WXVhKSzVyPUOwJO69VQ>? NWmxT2VROjRyOEizPFI>
GTL-16 NF7xSlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTFTWM2OD1|MDFOwG0> MmTpNlQxQDh|OEK=
MKN74 MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPWTWM2OD1|MDFOwG0> NY\LbJg4OjRyOEizPFI>
PAMC82 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnoTVl6UUN3ME2zNEDPxE1? MWCyOFA5QDN6Mh?=
LNCaP NFy1VoFHfW6ldHnvckBCe3OjeR?= MUK1JO69VQ>? NYDrTpF7OC1{NDDo MnvGbY5lfWOnczDBT3RUPDd|IHHu[EBCU1SWM{C4JJBpd3OyaH;yfYxifGmxbjDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= MViyN|k3PjZ{MR?=
C4-2  M1LURmZ2dmO2aX;uJGF{e2G7 MV61JO69VQ>? NG\ubIgxNTJ2IHi= NGDvdlJqdmS3Y3XzJGFMXFN2N{OgZY5lKEGNVGSzNFgheGixc4Doc5J6dGG2aX;uJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy Mn\pNlM6PjZ4MkG=
LNCaP MmDHSpVv[3Srb36gRZN{[Xl? MUm1JO69VQ>? NGXoXHMxNTJ2IHi= M3rUfIlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViZHnzeIFtKEGNVD3wZZRpf2G7IHLpc41iemuncoOgbY5kdHWmaX7nJHBTSVN2MDyg[WlHPEVuIETFMWJROSxibWTPVkwh[W6mIGC3NEBUPiCtaX7hd4UhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NEj5SlczOzl4Nk[yNS=>
C4-2  Ml2ySpVv[3Srb36gRZN{[Xl? MWS1JO69VQ>? NYP0NZZ4OC1{NDDo NGqwOJNqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhfGinIHTpd5RidCCDS2StdIF1cHejeTDibY9u[XKtZYLzJIlv[2y3ZHnu[{BRWkGVNECsJIVKTjSHLDC0SU1DWDFuIH3UU3ItKGGwZDDQO|AhWzZia3nuZZNmKGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz NFn1NGgzOzl4Nk[yNS=>
LNCaP MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfsSIFlOS1zMECwNEBvVQ>? NWK2c5lMOC1|IHS= M1jsbolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NVPJcJh3OjN7Nk[2NlE>
C4-2  MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzxdZJEOS1zMECwNEBvVQ>? NH3TT2QxNTNiZB?= MnrpbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M1XuflI{QTZ4NkKx
LNCaP NXzwWZFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\mV2RnOTByLUWwNFAhdk1? MVi3NkBp M4nSZYlv[3KnYYPld{B1cGViZoLhZ5Rqd25ib3[gZ4VtdHNidX7k[ZJod2mwZzDj[YxtKGSnYYTo MoHhNlM6PjZ4MkG=
C4-2  NXHJTJNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYqxNFAuPTByMDDuUS=> NWPDV4tUPzJiaB?= MkfLbY5kemWjc3XzJJRp\SCocnHjeIlwdiCxZjDj[YxteyC3bnTldodwcW6pIHPlcIwh\GWjdHi= NITicFUzOzl4Nk[yNS=>
PC-3 NFf0UmRHfW6ldHnvckBCe3OjeR?= NGXxW40xNjVxMT:xNEDPxE1? M1rSSlQ5KGh? NGLi[HZld3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkO1NlMzPTh5NEC=
DU145  MXHGeY5kfGmxbjDBd5NigQ>? MnG0NE42NzFxMUCg{txO MXi0PEBp MmnC[I94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJIRwf26|dILlZY0heGG2aIfhfUBxem:2ZXnud{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXmyN|I2QDd2MB?=
LNCaP Mnj0R4VtdCCYaXHibYxqfHliQYPzZZk> MkXBNE0yODByIH7N MWCwMVQh\A>? MX7y[YR2[2WmIFzOR4FRKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh M3fIeVI{OjV6N{Sw
PC-3  M{H3e2Z2dmO2aX;uJGF{e2G7 NVjJdYh3OTBizszN NWXFd2lbOTJiaB?= MX7pcoR2[2W|IHH1eI9xcGGpeR?= NXroZlN6OjN{NUi3OFA>

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-d-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. [2]

Protocol

Kinase Assay:[1]
+ Expand

Caliper Off-Chip Incubation Mobility Shift assay:

The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K m for each AKT isoform; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: [2]
+ Expand
  • Cell lines: 182 solid and hematologic tumor cell lines
  • Concentrations: ~30 μM
  • Incubation Time: 72 hours
  • Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO2. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts.
  • Formulation: In 10% DMSO 25% w/v Kleptose HPB
  • Dosages: 130 mg/Kg - 300 mg/Kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (200.5 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.92
Formula

C21H25ClN6O2

CAS No. 1143532-39-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03772561 Recruiting Solid Tumor Adult National University Hospital Singapore December 3 2018 Phase 1
NCT03772561 Recruiting Solid Tumor Adult National University Hospital Singapore December 3 2018 Phase 1
NCT03310541 Recruiting Breast Cancer|Prostate Cancer|Advanced Solid Tumors Memorial Sloan Kettering Cancer Center October 11 2017 Phase 1
NCT03310541 Recruiting Breast Cancer|Prostate Cancer|Advanced Solid Tumors Memorial Sloan Kettering Cancer Center October 11 2017 Phase 1
NCT03182634 Recruiting Advanced Breast Cancer Institute of Cancer Research United Kingdom|Royal Marsden NHS Foundation Trust December 15 2016 Phase 2
NCT03182634 Recruiting Advanced Breast Cancer Institute of Cancer Research United Kingdom|Royal Marsden NHS Foundation Trust December 15 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products4

Tags: buy Capivasertib (AZD5363) | Capivasertib (AZD5363) supplier | purchase Capivasertib (AZD5363) | Capivasertib (AZD5363) cost | Capivasertib (AZD5363) manufacturer | order Capivasertib (AZD5363) | Capivasertib (AZD5363) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID